Loading…
Stem Cell Therapeutic and Research Reauthorization Act of 2025
Legislative Progress
Introduced
September 4, 2025
Latest Action
July 21, 2026
Primary Sponsor
Christopher H. SmithRepublican(NJ)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
97pct
320d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (8)
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 464.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4642)
DEBATE - The House proceeded with forty minutes of debate on H.R. 5160.
Considered under suspension of the rules. (consideration: CR H4642-4643)
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 629.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-724.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by the Yeas and Nays: 48 - 0.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2026 · third_quarter · Health Issues
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Clinical Trial Modernization Act, H.R. 3521, S. 4440. Increase access to clinical trials for all persons with cancer to participate by reducing barriers to enrollment including support for and remote access to trials.
Client expense: $310,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (H.R. 5160/S. 4109).
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2026 · third_quarter · Budget/Appropriations
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES
2026 · third_quarter · Health Issues
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Transplant related issues, generally Monitor the following: Transplant courier issues FDA, Laboratory Developed Tests related issues Public Law 119-21, One Big Beautiful Bill Act, Health care coverage related issues
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications OMB Uniform Guidance Oversight H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Retirement
ERISA preemption Oversight of EBSA programs - EBSA Investigations Transparency Act (2869); Transparency for Secret Litigation Agreements (HR 2958) Alternative investments in qualified retirement plans Pooled Employer Plans Collective investment trusts (CITs) and insurance company separate accounts HR 1013 and HR 3383 ERISA Litigation Reform Act (HR 6084) Limited Scope Audit Prohibited Transaction Exemption (PTE) 77-4 INSIGHT Act (Sen. Banks) Pension Benefit Guaranty Corporation single-employer premiums Market Based Cash Balance Plans Age of participation in retirement plans reduced from 21 to 18 (HR 4718 / S. 1707) Permitting optional re-enrollment, S. 1831 Defined Benefit Pension Plans (DBs), retiree health accounts, IRC sec. 401(h) limited access to surplus, S. 2003 Child Saving Accounts (IRC sec. 530A, Trump Accounts) Retire Through Ownership Act, HR 5160 / S. 2403
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Labor, Dept of (DOL), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
2026 · second_quarter · Health Issues
Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109.
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Budget/Appropriations
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Issues related to HRSA's regulation of cord blood storage and the Stem Cell Therapeutic and Research Reauthorization Act (HR5160/S4109).
Client expense: Not reported · Firm income: $90,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2026 · second_quarter · Health Issues
Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act S. 4440/H.R. 3521 - The Clinical Trial Modernization Act
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2026 · second_quarter · Health Issues
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Transplant related issues, generally Monitor the following: Transplant courier issues FDA, Laboratory Developed Tests related issues Public Law 119-21, One Big Beautiful Bill Act, Health care coverage related issues
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
2026 · first_quarter · Health Issues
Alleviating Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160/S. 4109. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Sickle Cell Disease Comprehensive Care Act (House and Senate), H.R. 5178/S. 721. Lowering Costs for Caregives Act (House and Senate), S. 1565/H.R. 138.
Client expense: $320,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Labor-HHS Appropriations Billing and Coding classifications CAR-T Therapy Clarifications Revaccination of Immunosuppressed Patients H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160/S.4109, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2026 · first_quarter · Budget/Appropriations
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Federal funding for NCBI, passage of H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Issues related to nutrition, physical activity and Kindergarten Readiness Issues related to pediatric research coordinating function at NIH Issues related to 340B Issues related to maternal health S. 2355, Patients Deserve Price Tags Act H.R. 5469 & S. 2858, SHINE for Autumn Act H.R. 6238 & S. 3254 NIH IMPROVE Act H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R. 4709, Newborn Screening Saves Lives Reauthorization Act of 2025
Client expense: $150,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues S.4109, Stem Cell Therapeutic and Research Reauthorization Act of 2026, Entirety Monitor the following: Transplant courier issues FDA, Laboratory Developed Tests related issues Public Law 119-21, One Big Beautiful Bill Act, Health care coverage related issues
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Retirement
ERISA preemption Oversight of EBSA programs - EBSA Investigations Transparency Act (2869); Transparency for Secret Litigation Agreements (HR 2958) Alternative investments in qualified retirement plans Pooled Employer Plans Collective investment trusts (CITs) and insurance company separate accounts HR 1013 and HR 3383 ERISA Litigation Reform Act (HR 6084) Limited Scope Audit Prohibited Transaction Exemption (PTE) 77-4 INSIGHT Act (Sen. Banks) Pension Benefit Guaranty Corporation single-employer premiums Market Based Cash Balance Plans Age of participation in retirement plans reduced from 21 to 18 (HR 4718 / S. 1707) Permitting optional re-enrollment, S. 1831 Defined Benefit Pension Plans (DBs), retiree health accounts, IRC sec. 401(h) limited access to surplus, S. 2003 Child Saving Accounts (IRC sec. 530A, Trump Accounts) Retire Through Ownership Act, HR 5160 / S. 2403
Client expense: $230,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), Labor, Dept of (DOL), Pension Benefit Guaranty Corporation (PBGC), SENATE, Securities & Exchange Commission (SEC), Treasury, Dept of
2026 · first_quarter · Health Issues
Stem Cell Therapeutic and Research Reauthorization Act (SCTRRA) (S. 4109/H.R. 5160)
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Health Issues
Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
2026 · first_quarter · Budget/Appropriations
Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
2026 · first_quarter · Medical/Disease Research/Clinical Labs
Federal funding for NCBI, H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act
Client expense: Not reported · Firm income: Not reported
2025 · fourth_quarter · Health Issues
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues Monitor the following: Transplant courier issues FDA, Laboratory Developed Tests Rule VALID Act, Laboratory developed issues Public Law 119-21, One Big Beautiful Bill Act, Health care coverage related issues
Client expense: Not reported · Firm income: $120,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Health Issues
Labor-HHS Appropriations Billing and Coding CAR-T Therapy Clarifications Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025 H.R.1262/S.932, the Give Kids a Chance Act
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2025 · fourth_quarter · Health Issues
Alleviating Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Sickle Cell Disease Comprehensive Care Act (House and Senate), H.R. 5178/S. 721.
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Alleviating Barriers for Caregivers (House and Senate), S. 1227/H.R. 2491. Reauthorization of C.W. Bill Young Cell Transplantation Program (House and Senate), H.R. 5160. Accelerating Kids Access to Care Act (House and Senate), S. 752/H.R. 1509. Credit for Caring Act (House and Senate), S. 925/H.R. 2036. Clinical Trial Modernization Act (House), H.R. 3521. Reauthorization of the Enhanced Advance Premium Tax Credit (House and Senate).
Client expense: $290,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · Health Issues
Labor-HHS Appropriations Billing and Coding CAR-T Therapy Clarifications Revaccination of Immunosuppressed Patients Patient-Care Episode Financial Toxicity NIH Funding Cancer Moonshot H.R. 1509/S. 752, The Accelerating Kids Access to Care Act H.R. 2491/S. 1227, Alleviating Barriers to Care Act H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025
Client expense: Not reported · Firm income: $70,000
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
2025 · third_quarter · Health Issues
H.R.5160, Stem Cell Therapeutic and Research Reauthorization Act of 2025, Cellular Transplant related issues and initiatives; and Reauthorization related issues Transplant courier issues Monitor the following: FDA, Laboratory Developed Tests Rule VALID Act, Laboratory developed issues Public Law 119-21, One Big Beautiful Bill Act, Health care coverage related issues
Client expense: Not reported · Firm income: $110,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| September 4, 2025 |
| Democratic |
| ME |
| Claudia Tenney | Republican | NY |
| Cliff Bentz | Republican | OR |
| Debbie Dingell | Democratic | MI |
| Doris O. Matsui | Democratic | CA |
| Eleanor Holmes Norton | Democratic | DC |
| Eugene Simon Vindman | Democratic | VA |
| Gus M. Bilirakis | Republican | FL |
| Josh Gottheimer | Democratic | NJ |
| Kathy Castor | Democratic | FL |
| Kelly Morrison | Democratic | MN |
| Kweisi Mfume | Democratic | MD |
| Michael Lawler | Republican | NY |
| Michelle Fischbach | Republican | MN |
| Nanette Diaz Barragán | Democratic | CA |
| Nicole Malliotakis | Republican | NY |
| Robert B. Aderholt | Republican | AL |
| Sharice Davids | Democratic | KS |